Main Article Content


The present paper describes a series of single-case evaluations of the effects of bromocriptine, a dopamine D2 post-synaptic receptor agonist  in 13 patients with clinical features cf abulia. Method - An open trial in seven males and six females who had either traumatic brain injury or subarachnoid haemorrhage between two months and five years previously. After repeated baseline assessments, bromocriptine was administered in gradually increasing doses, Assessments were repeated at increasing doses, during maintenance, and after withdrawal. Same newly developed structured instruments for quantifying motivation were  used; measures of anxiety and depression, and cognitive tests sensitive to motivation were also administered. Results- Following bromocriptine treatment improved on all scores measured other than mood. Improvement was maintained after bromocriptine withdrawal in nine of the patients. Conclusion- Abulia in patients with brain injury may result from dysfunction in the mesocorticolimbic dopaminergic cirucity, giving rise to associated deficiencies in reward responsiveness and cognitive function. New rating are propsed of motivation in brain injured patients.


Abulia motivation rewards dopamine bromocriptine functional recovery traumatic brain injury subarachnoids haemorrhages drug therapy cognitive-processes

Article Details

How to Cite
ALl-Adawi, S., Powell, J., Basavappa, S., & Greenwood, R. (2020). Abulia: The Pathology of "Will" and Dopaminergic Dysfunction in Brain-Injured Patients. Sultan Qaboos University Medical Journal, 1(1), 27–40. Retrieved from

Similar Articles

You may also start an advanced similarity search for this article.